OPSYNVI: payments to doctors
Payments that named OPSYNVI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $173K
- Providers
- 3,063
- Transactions
- 4,332
- Average per transaction
- $40
The per-transaction average — $40 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,063 providers the average total is $56, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $171,391 | 99.2% |
| Johnson & Johnson | $1,331 | 0.8% |